Improving the hit-to-lead process: data-driven assessment of drug-like and lead-like screening hits (Q31034164)

28 June 2017

1 reference

title

Improving the hit-to-lead process: data-driven assessment of drug-like and lead-like screening hits (English)

1 reference

28 June 2017

0 references

Tobias Wunberg

1 reference

28 June 2017

Martin Hendrix

1 reference

28 June 2017

Alexander Hillisch

1 reference

28 June 2017

Mario Lobell

1 reference

28 June 2017

Heinrich Meier

1 reference

28 June 2017

Carsten Schmeck

1 reference

28 June 2017

Hanno Wild

1 reference

28 June 2017

Berthold Hinzen

1 reference

28 June 2017

publication date

1 February 2006

1 reference

28 June 2017

1 reference

28 June 2017

1 reference

28 June 2017

issue

3-4

1 reference

28 June 2017

page(s)

175-180

1 reference

Stategic trends in the drug industry

28 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903700-1

7 January 2021

Fragment-based lead discovery

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903700-1

7 January 2021

Nonleadlikeness and leadlikeness in biochemical screening

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903700-1

7 January 2021

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903700-1

7 January 2021

Drugs, leads, and drug-likeness: an analysis of some recently launched drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903700-1

7 January 2021

Is there a difference between leads and drugs? A historical perspective

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903700-1

7 January 2021

High-throughput drug discovery: what can we expect from HTS?

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903700-1

7 January 2021

Ligand efficiency: a useful metric for lead selection

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903700-1

7 January 2021

Hit and lead generation: beyond high-throughput screening

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903700-1

7 January 2021

Organic chemistry in drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903700-1

7 January 2021

Lead generation--enhancing the success of drug discovery by investing in the hit to lead process

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903700-1

7 January 2021

Design and discovery of small molecules targeting raf-1 kinase

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903700-1

7 January 2021

Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903700-1

7 January 2021

The new pre-preclinical paradigm: compound optimization in early and late phase drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903700-1

7 January 2021

Decision support systems in drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903700-1

7 January 2021

Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903700-1

7 January 2021

Molecular properties that influence the oral bioavailability of drug candidates

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903700-1

7 January 2021

10.1016/S1359-6446(05)03700-1

Identifiers

DOI

1 reference

28 June 2017

1 reference